Sitravatinib/Tislelizumab Combo Active in Advanced Ovarian Cancer

Virgina Powers, PhD
Published: Wednesday, Jan 01, 2020
Bo Gao, MD, PhD, of the Oncology Department at Blacktown Cancer and Hematology Centre, Australia

Bo Gao, MD, PhD

The novel combination of sitravatinib and tislelizumab showed encouraging antitumor activity and a manageable safety profile in patients with advanced ovarian cancer, according to results of the phase Ib BGB-900-103 study (NCT03666143) reported at the 2019 ESMO Immuno-Oncology Congress.1

Of the 17 efficacy-evaluable patients in a cohort of 20 heavily pretreated patients with platinum-resistant advanced ovarian cancer, the confirmed objective response rate (ORR) was 23.5% (95% CI, 6.8-49.9). The best response was a partial response (PR), which was achieved by 7 patients; of these, PRs were confirmed in 4 patients and remained unconfirmed at the data cutoff in 3 patients.

“Combination treatment with sitravatinib and tislelizumab showed manageable safety and promising antitumor activity that was supported by 7 patients with PR and 8 patients with stable disease out of 17 patients with advanced ovarian cancer,” said lead study author Bo Gao, MD, PhD, of the Oncology Department at Blacktown Cancer and Haematology Centre, Australia. “Further investigation of this combination is warranted in patients with ovarian cancer,” added Gao.

Sitravatinib is an investigational, orally bioavailable spectrum selective RTK inhibitor with activity against TYRO3, Axl, Mer, VEGFR2, and KIT, whereas tislelizumab (BGB-A317) is an investigational, humanized IgG4 monoclonal antibody with high affinity binding to PD-1.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x